Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study

Voort, Ella A.M. van der; Koehler, Edith M.; Dowlatshahi, Emmilia; Hofman, Albert; Stricker, Bruno H.; Janssen, Harry L A; Schouten, Jeoffrey N.L.; Nijsten, Tamar

doi:10.1016/j.jaad.2013.10.044

Cited by 142 publications

(110 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among 2292 participants, 118 (5.1%) were affected by psoriasis and the prevalence of NAFLD was 46.2% in psoriatic patients compared with 33.3% of participants without psoriasis. Thus, after adjustment for alcohol consumption, smoking status, presence of MetS components and alanine aminotransferase, psoriasis remained a significant predictor of NAFLD [52] .…”

Section: Psoriasis and Hypertensionmentioning

confidence: 93%

“…Moreover, patients with psoriasis and NAFLD showed metabolic syndrome and higher serum C-reactive protein [51] . Van der Voort et al [52] in 2013 conducted a large prospective population-based cohort study in subjects up to 55 years. Among 2292 participants, 118 (5.1%) were affected by psoriasis and the prevalence of NAFLD was 46.2% in psoriatic patients compared with 33.3% of participants without psoriasis.…”

Section: Psoriasis and Hypertensionmentioning

confidence: 99%

See 1 more Smart Citation

Non-alcoholic fatty liver disease and psoriasis: So far, so near

Ganzetti

Campanati

Offidani

2015

WJH

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory immune-mediated skin diseases which is frequently associated to comorbidities. Non-alcoholic fatty liver disease (NAFLD) is defined as an excessive accumulation of triglycerides in hepatocytes and includes a wide spectrum of liver conditions ranging from relatively benign steatosis to non-alcoholic steatohepatitis with fatty infiltration and lobular inflammation and to cirrhosis and endstage liver disease. Actually, psoriasis is considered a systemic diseases associated to comorbidities, as metabolic syndrome and NAFLD is seen the hepatic manifestation of the metabolic syndrome. The possible link between psoriasis, obesity and metabolic syndrome, which are known risk factors for NAFLD has been recently documented focusing in the crucial role of the adipose tissue in the development of the inflammatory background sharing by the above entities. According to recent data, patients with psoriasis show a greater prevalence of NAFLD and metabolic syndrome than the general population. Moreover, patients with NAFLD and psoriasis are at higher risk of severe liver fibrosis than those with NAFLD and without psoriasis. The link between these pathological conditions appears to be a chronic low-grade inflammatory status. The aim of this review is to focus on the multiple aspects linking NAFLD and psoriasis, only apparently far diseases. Core tip: The review focuses on the multiple physiopathogenetic aspects of the possible link between psoriasis and non-alcoholic fatty liver disease (NAFLD) emphasizing the most recent scientific data. The importance of the multidisciplinary approach to patients affected by psoriasis is underlined and the therapeutic options to treat concomitant psoriasis and NAFLD is discussed evaluating the risk benefit of both biologic and non-biologic therapies.Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol 2015; 7(3): 315-326 Available from:

show abstract

Section: Psoriasis and Hypertensionmentioning

confidence: 93%

Section: Psoriasis and Hypertensionmentioning

confidence: 99%

Non-alcoholic fatty liver disease and psoriasis: So far, so near

Ganzetti

Campanati

Offidani

2015

WJH

View full text Add to dashboard Cite

show abstract

“…NAFLD was diagnosed in 46.2% of patients with psoriasis compared with 33.3% of the controls (p=0.005) [17]. Psoriasis was found associated to NAFLD independently of alcohol consumption, smoking status, presence of metabolic syndrome and serum levels of alanine aminotransferase (adjusted OR 1.7, 95% CI 1.1-2.6) [17]. This is noteworthy as excess liver fat promotes hepatic insulin resistance, and NAFLD is recognized risk factor for diabetes [18,19].…”

Section: Chronic Plaque Psoriasis and Diabetes The Epidemiological Ementioning

confidence: 99%

“…Our findings have been also confirmed in a recent Dutch study. NAFLD was diagnosed in 46.2% of patients with psoriasis compared with 33.3% of the controls (p=0.005) [17]. Psoriasis was found associated to NAFLD independently of alcohol consumption, smoking status, presence of metabolic syndrome and serum levels of alanine aminotransferase (adjusted OR 1.7, 95% CI 1.1-2.6) [17].…”

Section: Chronic Plaque Psoriasis and Diabetes The Epidemiological Ementioning

confidence: 99%

Systemic therapy of psoriasis in diabetic patients

Gisondi¹,

Perazzolli²,

Giglio³

et al. 2015

Glob Dermatol

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease affecting 2-3% of worldwide population. Moderate to severe psoriasis is frequently associated with metabolic disorders including diabetes, obesity, dyslipidaemia, metabolic syndrome and non-alcoholic fatty liver disease. In particular, the prevalence of diabetes in patients with psoriasis ranges from 5 to 54%. Most of the studies found that the prevalence of diabetes is higher in patients with moderate to severe psoriasis compared to mild disease. The association between psoriasis and diabetes could be explained considering several factors including a common genetic background, the high prevalence of metabolic risk factors for diabetes in patients with psoriasis as well as unhealthy life-styles such heavy drinking, over-eating and sedentary, which are common in patients with psoriasis. From a clinical prospective, the understanding of the patients in the context of metabolic comorbidities including diabetes is very important to ensure that treatment is tailored to meet the individual patient needs. Indeed, some pharmacological treatments may negatively affect metabolic comorbidities, and have important interactions with drugs that are commonly used to treat them. Non-pharmacological intervention such as diet and physical exercise could both improve the response to treatments for psoriasis and reduce the risk of diabetes and cardiovascular events.

show abstract

“…Данные изме-нения отражают проявления неалкогольной жировой бо-лезни печени, которая формируется в результате жировой инфильтрации и очагового воспаления гепатоцитов при отсутствии чрезмерного употребления алкоголя. Следо-вательно, неалкогольная жировая болезнь печени явля-ется фактором риска развития псориатического артрита у больных псориазом [24,25]. Таким образом, причинно-следственная взаимосвязь заболеваний гепатобилиарной системы с клиническим течением псориаза и псориати-ческого артрита подтверждается наличием изменений основных клинико-лабораторных и инструментальных показателей и характеризуется разнообразными про-явлениями, включая дисфункцональные расстройства, симптомы некалькулезного хронического холецистита, неалкогольной жировой болезни печени [21].…”

Section: обсуждение основного результата исследованияunclassified

Hepatobiliary system diseases as the predictors of psoriasis progression

2016

View full text Add to dashboard Cite

Псориаз (ПС) -хроническое системное рецидивиру-ющее заболевание, проявляющееся гиперпролиферацией кератиноцитов и характеризующееся поражением раз-личных органов и систем с преимущественным вовлече-нием в патологический процесс кожи [1−4]. Актуальность изучения ПС обусловлена высокой распространенностью заболевания, формированием тяжелых и резистентных к проводимой терапии форм, повышением смертности больных, недостаточной эффективностью существующих методов патогенетического и симптоматического лече-ния [5]. Одной из наиболее тяжелых клинических форм прогрессирования ПС с формированием необратимых инвалидизирующих костно-деструктивных повреждений является псориатический артрит (ПсА) [6,7]. S.V. Smirnova

show abstract

Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study

Cited by 142 publications

References 39 publications

Non-alcoholic fatty liver disease and psoriasis: So far, so near

Non-alcoholic fatty liver disease and psoriasis: So far, so near

Systemic therapy of psoriasis in diabetic patients

Hepatobiliary system diseases as the predictors of psoriasis progression

Contact Info

Product

Resources

About